Implant provides long-acting treatment for prostate cancer

Article

Luteinizing hormone-releasing hormone (LHRH) agonists are a mainstay in treating locally advanced and metastatic prostate cancer, with the U.S. market for these therapies representing more than $1 billion in annual sales. The market is dominated by four-month and shorter depot injections and implants, such as leupro-lide acetate (Lupron, TAP Pharmaceuticals) for depot suspension and goserelin acetate (Zoladex, Astra Zeneca) implant.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Related Content
© 2025 MJH Life Sciences

All rights reserved.